secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001437749-25-027241
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin shareholders approve 5x authorized share increase and reverse split authority
--------------------------------------------------------------------------------

- Authorized common shares increased from 100M to 500M (Proposal 8).
- Reverse stock split up to 1:20 authorized (Proposal 9); timing not disclosed.
- Share issuance for June 23, 2025 warrants (up to 148.7M shares) approved (Proposal 6).
- Equity incentive plan shares increased (Proposal 3); say-on-pay approved (Proposal 4).
- Supermajority voting amendment failed (Proposal 7); all 6 directors re-elected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925027241/0001437749-25-027241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925027241/mbrx20250818c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-027241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer